Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $31.49 million. The enterprise value is $259.63 million.
Important Dates
The next estimated earnings date is Tuesday, May 19, 2026, after market close.
| Earnings Date | May 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 63.48 million shares outstanding. The number of shares has increased by 0.13% in one year.
| Current Share Class | 63.48M |
| Shares Outstanding | 63.48M |
| Shares Change (YoY) | +0.13% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 15.54% |
| Float | 42.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.11 |
| Forward PS | n/a |
| PB Ratio | 0.43 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 0.39 |
| P/OCF Ratio | 0.38 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 24.81, with an EV/FCF ratio of 3.27.
| EV / Earnings | n/a |
| EV / Sales | 0.94 |
| EV / EBITDA | 24.81 |
| EV / EBIT | n/a |
| EV / FCF | 3.27 |
Financial Position
The company has a current ratio of 0.90, with a Debt / Equity ratio of 2.25.
| Current Ratio | 0.90 |
| Quick Ratio | 0.56 |
| Debt / Equity | 2.25 |
| Debt / EBITDA | 15.92 |
| Debt / FCF | 3.01 |
| Interest Coverage | -0.09 |
Financial Efficiency
Return on equity (ROE) is -27.58% and return on invested capital (ROIC) is -0.59%.
| Return on Equity (ROE) | -27.58% |
| Return on Assets (ROA) | -0.23% |
| Return on Invested Capital (ROIC) | -0.59% |
| Return on Capital Employed (ROCE) | -1.09% |
| Weighted Average Cost of Capital (WACC) | 9.41% |
| Revenue Per Employee | $368,314 |
| Profits Per Employee | -$318,985 |
| Employee Count | 751 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.02 |
Taxes
In the past 12 months, BIOX has paid $8.33 million in taxes.
| Income Tax | 8.33M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.37% in the last 52 weeks. The beta is 0.53, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | -88.37% |
| 50-Day Moving Average | 0.52 |
| 200-Day Moving Average | 1.59 |
| Relative Strength Index (RSI) | 44.39 |
| Average Volume (20 Days) | 415,313 |
Short Selling Information
The latest short interest is 934,995, so 1.47% of the outstanding shares have been sold short.
| Short Interest | 934,995 |
| Short Previous Month | 1.20M |
| Short % of Shares Out | 1.47% |
| Short % of Float | 2.18% |
| Short Ratio (days to cover) | 1.11 |
Income Statement
In the last 12 months, BIOX had revenue of $276.60 million and -$239.56 million in losses. Loss per share was -$3.77.
| Revenue | 276.60M |
| Gross Profit | 103.66M |
| Operating Income | -2.54M |
| Pretax Income | -54.14M |
| Net Income | -239.56M |
| EBITDA | 10.47M |
| EBIT | -2.54M |
| Loss Per Share | -$3.77 |
Full Income StatementBalance Sheet
The company has $11.06 million in cash and $239.46 million in debt, giving a net cash position of -$228.39 million or -$3.60 per share.
| Cash & Cash Equivalents | 11.06M |
| Total Debt | 239.46M |
| Net Cash | -228.39M |
| Net Cash Per Share | -$3.60 |
| Equity (Book Value) | 106.62M |
| Book Value Per Share | 1.20 |
| Working Capital | -34.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $81.87 million and capital expenditures -$2.37 million, giving a free cash flow of $79.50 million.
| Operating Cash Flow | 81.87M |
| Capital Expenditures | -2.37M |
| Depreciation & Amortization | 13.00M |
| Net Borrowing | -68.73M |
| Free Cash Flow | 79.50M |
| FCF Per Share | $1.25 |
Full Cash Flow StatementMargins
Gross margin is 37.48%, with operating and profit margins of -0.92% and -86.61%.
| Gross Margin | 37.48% |
| Operating Margin | -0.92% |
| Pretax Margin | -19.57% |
| Profit Margin | -86.61% |
| EBITDA Margin | 3.78% |
| EBIT Margin | -0.92% |
| FCF Margin | 28.74% |